Short Information | Novartis AG (NYSE:NVS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 108,864 |
Total Actual Volume | 27,165,223 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 5,443 |
Average Short Percentage | 0.43% |
Is there a NVS Short Squeeze or Breakout about to happen?
See the NVS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-01-2024 | $106.58 | $106.54 | $107.62 | $106.3 | 1,194,262 | 5,367 | 0.45% |
06-28-2024 | $106.75 | $106.46 | $107.12 | $106.235 | 1,516,862 | 11,716 | 0.77% |
06-27-2024 | $106.65 | $106.55 | $106.78 | $106.11 | 1,268,678 | 16,494 | 1.3% |
06-26-2024 | $106.76 | $107.07 | $107.34 | $106.53 | 1,547,216 | 4,926 | 0.32% |
06-25-2024 | $107.22 | $107.37 | $107.4 | $106.79 | 819,381 | 5,791 | 0.71% |
06-24-2024 | $107.47 | $106.95 | $107.67 | $106.91 | 1,551,184 | 2,872 | 0.19% |
06-21-2024 | $105.39 | $105.22 | $105.71 | $104.44 | 1,302,106 | 1,487 | 0.11% |
06-20-2024 | $104.66 | $105.74 | $105.85 | $104.4 | 1,285,660 | 1,985 | 0.15% |
06-18-2024 | $105.33 | $104.94 | $105.57 | $104.86 | 1,051,803 | 4,473 | 0.43% |
06-17-2024 | $104.44 | $104.93 | $105.155 | $104.23 | 997,144 | 8,068 | 0.81% |
06-14-2024 | $106.66 | $105.72 | $106.77 | $104.95 | 2,565,119 | 1,466 | 0.06% |
06-13-2024 | $105.78 | $106.02 | $106.19 | $104.94 | 1,077,649 | 1,680 | 0.16% |
06-12-2024 | $106.33 | $105.55 | $106.37 | $105.52 | 1,938,974 | 13,147 | 0.68% |
06-11-2024 | $104.98 | $104.51 | $104.98 | $104.205 | 1,523,217 | 5,034 | 0.33% |
06-10-2024 | $105.07 | $105.4 | $105.46 | $104.7811 | 1,255,773 | 3,974 | 0.32% |
06-07-2024 | $106.195 | $105.33 | $106.215 | $105.26 | 849,684 | 3,879 | 0.46% |
06-06-2024 | $105.68 | $106.13 | $106.46 | $105.65 | 1,031,381 | 6,549 | 0.63% |
06-05-2024 | $105.47 | $105.36 | $105.59 | $105.06 | 1,109,131 | 3,838 | 0.35% |
06-04-2024 | $103.82 | $104.92 | $104.95 | $103.51 | 1,685,683 | 3,844 | 0.23% |
06-03-2024 | $103.23 | $102.76 | $103.7 | $102.72 | 1,594,316 | 2,274 | 0.14% |
News, Short Squeeze, Breakout and More Instantly...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demons...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo PR Newswire Secondary endpoint data for estimated glomerular filtration rate (eGF...